维普中文期刊产品整合服务

Toxic epidermal necrolysis related to AP(pemetrexed plus cisplatin)and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer

查看全文 作　　者：Ji-Jie [1,2,3]Huang;Shu-Xiang [1,2,3]Ma;Xue [1,2,3]Hou;Zhao [1,2,3]Wang;Yin-Duo [1,2,3]Zeng;Tao [1,2,3]Qin;Xiao-Xiao [1,2,3]Dinglin;Li-Kun [1,2,3]Chen 高影响力作者 机构地区：[1]Department of Medical Oncology, Sun Yatsen University Cancer Center;[2]State Key Laboratory of Oncology in South China;[3]Collaborative Innovation Center for Cancer Medicine高影响力机构 出　　处：《Chinese Journal of Cancer》索引2015年第34卷第2期,共5页高影响力期刊 摘　　要：Toxic epidermal necrolysis(TEN) is a rare acute life-threatening mucocutaneous disorder that is mostly drug-related(80%-95%). It is clinically characterized as a widespread sloughing of the skin and mucosa. AP regimen(pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous non-small cell lung cancer(NSCLC). Gefitinib, a small-molecule epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI), has already been recommended as a first-line treatment in EGFR-mutant metastatic NSCLC. We report rare presentation of TEN involving adverse effects of AP and gefitinib combination treatment in a 42-year-old woman diagnosed with metastatic NSCLC harboring an EGFR mutation. On the 21 st day after administration of the first cycle of AP regimen and the 8th day after the initiation of gefitinib treatment, she developed an acne-like rash, oral ulcer, and conjunctivitis, which later became blisters and ultimately denuded. The characteristic clinical courses were decisive for the diagnosis of TEN. Treatment with systemic steroids and immunoglobulin as well as supportive treatment led to an improvement of her general condition and a remarkable recovery. 关 键 词：表皮生长因子受体 非小细胞肺癌 转移性 中毒性 AP 顺铂 坏死 酪氨酸激酶抑制剂
相关文献

参考文献(15)

引证文献(2)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费